NI201500022A - Formulaciones de trans-clomifeno y usos de las mismas - Google Patents

Formulaciones de trans-clomifeno y usos de las mismas

Info

Publication number
NI201500022A
NI201500022A NI201500022A NI201500022A NI201500022A NI 201500022 A NI201500022 A NI 201500022A NI 201500022 A NI201500022 A NI 201500022A NI 201500022 A NI201500022 A NI 201500022A NI 201500022 A NI201500022 A NI 201500022A
Authority
NI
Nicaragua
Prior art keywords
trans
clomiphene
cancer
solvates
pharmaceutically acceptable
Prior art date
Application number
NI201500022A
Other languages
English (en)
Spanish (es)
Inventor
S Podolski Joseph
Hsu Kuang
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48014380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201500022(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of NI201500022A publication Critical patent/NI201500022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NI201500022A 2012-08-21 2015-02-17 Formulaciones de trans-clomifeno y usos de las mismas NI201500022A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261691722P 2012-08-21 2012-08-21

Publications (1)

Publication Number Publication Date
NI201500022A true NI201500022A (es) 2016-02-01

Family

ID=48014380

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500022A NI201500022A (es) 2012-08-21 2015-02-17 Formulaciones de trans-clomifeno y usos de las mismas

Country Status (22)

Country Link
US (1) US20150202167A1 (cg-RX-API-DMAC10.html)
EP (1) EP2887922A1 (cg-RX-API-DMAC10.html)
JP (2) JP2015527360A (cg-RX-API-DMAC10.html)
KR (1) KR20150041793A (cg-RX-API-DMAC10.html)
CN (1) CN104582686A (cg-RX-API-DMAC10.html)
AU (1) AU2013306393A1 (cg-RX-API-DMAC10.html)
BR (1) BR112015002288A2 (cg-RX-API-DMAC10.html)
CA (1) CA2880388A1 (cg-RX-API-DMAC10.html)
CL (1) CL2015000311A1 (cg-RX-API-DMAC10.html)
CR (1) CR20150096A (cg-RX-API-DMAC10.html)
EA (1) EA201590421A1 (cg-RX-API-DMAC10.html)
HK (1) HK1209636A1 (cg-RX-API-DMAC10.html)
IL (1) IL236911A0 (cg-RX-API-DMAC10.html)
IN (1) IN2015DN01698A (cg-RX-API-DMAC10.html)
MX (1) MX2015001912A (cg-RX-API-DMAC10.html)
NI (1) NI201500022A (cg-RX-API-DMAC10.html)
NZ (1) NZ704679A (cg-RX-API-DMAC10.html)
PH (1) PH12015500331A1 (cg-RX-API-DMAC10.html)
SG (2) SG10201704820SA (cg-RX-API-DMAC10.html)
UA (1) UA113324C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014031177A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201501124B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
EP3015453B1 (en) 2014-10-28 2016-10-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of Clomiphene
EP3015454A1 (en) 2014-10-28 2016-05-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Stable solid form of trans-Clomiphene citrate
US11737934B2 (en) 2015-10-14 2023-08-29 Qfix Systems, Llc MRI compatible patient trolley
CN108463453A (zh) * 2016-04-22 2018-08-28 意大利合成制造有限公司 用于制备具有针状晶体习性的柠檬酸恩氯米芬的方法
CA3098552A1 (en) 2019-11-14 2021-05-14 Apotex Inc. Processes for the preparation of zuclomiphene and intermediates thereof
CA3098725A1 (en) 2019-11-14 2021-05-14 Apotex Inc. Zuclpomiphene salts and crystalline forms thereof
CA3105944A1 (en) 2020-01-22 2021-07-22 Apotex Inc. Crystalline forms of zuclomiphene citrate
EP3907213A1 (en) 2020-05-04 2021-11-10 Pcas Processes for the production of isomerically pure or enriched cis-clomiphene
US11578025B2 (en) 2020-10-19 2023-02-14 Apotex Inc. Processes for the preparation of zuclomiphene intermediates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
CN1289075C (zh) * 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
RU2006138235A (ru) * 2004-03-31 2008-05-10 Трофоджен, Инк. (Us) Суперагонисты человеческих гликопротеиновых гормонов и способы их применения
EP1776098A1 (en) 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
TWI458478B (zh) * 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第2型糖尿病的反式氯米芬

Also Published As

Publication number Publication date
IL236911A0 (en) 2015-03-31
EA201590421A1 (ru) 2015-06-30
WO2014031177A1 (en) 2014-02-27
KR20150041793A (ko) 2015-04-17
PH12015500331A1 (en) 2015-04-20
CR20150096A (es) 2015-05-04
US20150202167A1 (en) 2015-07-23
JP2015527360A (ja) 2015-09-17
NZ704679A (en) 2016-02-26
SG10201704820SA (en) 2017-07-28
AU2013306393A1 (en) 2015-02-19
ZA201501124B (en) 2016-04-28
BR112015002288A2 (pt) 2017-07-04
SG11201500641TA (en) 2015-04-29
IN2015DN01698A (cg-RX-API-DMAC10.html) 2015-07-03
CA2880388A1 (en) 2014-02-27
HK1209636A1 (en) 2016-04-08
UA113324C2 (xx) 2017-01-10
CN104582686A (zh) 2015-04-29
EP2887922A1 (en) 2015-07-01
CL2015000311A1 (es) 2015-08-14
MX2015001912A (es) 2015-06-05
JP2017206562A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
BR112015002288A2 (pt) formulações de trans-clomifeno e usos das mesmas
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX2018006637A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
NI201400008A (es) Metabolitos de trans-clomifeno y usos de los mismos
MY176489A (en) Novel tricyclic compounds as anticancer agents
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
PE20151901A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
TR201816379T4 (tr) DNA-PK inhibitörleri.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
NZ710729A (en) Amatoxin derivatives
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
ECSP18034035A (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
PE20151979A1 (es) Compuestos quimicos
CO2017005588A2 (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2022003398A (es) Composicion micelar inmunoestimulante.